Adriamycin and the Heart
- 8 February 1979
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 300 (6), 310-312
- https://doi.org/10.1056/nejm197902083000610
Abstract
Doxorubicin, or adriamycin, is one of the most effective chemotherapeutic agents for cancer. It has an established role in the treatment of the acute leukemias and the lymphomas. In contrast to most other drugs, it has substantial activity in solid tumors as well. It is the single most effective agent in the treatment of breast cancer and soft-tissue sarcomas, and it has substantial activity in the childhood tumors, testicular cancer, gastric cancer, ovarian cancer and oat-cell carcinoma of the lung.1 The acute dose-limiting toxicity of this drug, as with most chemotherapeutic agents, is myelosuppression. Other side effects, including nausea, vomiting . . .Keywords
This publication has 6 references indexed in Scilit:
- Doxorubicin Cardiomyopathy: Evaluation by Phonocardiography, Endomyocardial Biopsy, and Cardiac CatheterizationAnnals of Internal Medicine, 1978
- Assessment of cardiac performance with quantitative radionuclide angiocardiography: sequential left ventricular ejection fraction, normalized left ventricular ejection rate, and regional wall motion.Circulation, 1977
- Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicityCancer, 1977
- Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor ResponseScience, 1977
- Cardiotoxicity of adriamycin and related anthracyclinesCancer Treatment Reviews, 1976
- The cardiotoxicity of adriamycin and daunomycin in childrenCancer, 1976